Print Page   Close Window

Press Release

James R. Butler Appointed to POZEN's Board of Directors

CHAPEL HILL, N.C.--(BUSINESS WIRE)--July 10, 2003--POZEN Inc. (NASDAQ: POZN) announced today the appointment of James R. Butler to its board of directors.

"We are delighted to welcome Jim to our board. He has a record of extraordinary success over his more than thirty-year career and has been associated with some of the most successful products in the pharmaceutical sector. I look forward to Jim's input as POZEN continues its growth and development," said John R. Plachetka, Pharm.D., chairman, president and chief executive officer of POZEN.

Mr. Butler is retired from ALZA Corporation where the last position he held was President of ALZA International. Prior to that, Mr. Butler worked at Glaxo Inc. for 23 years where the last position he held was Vice President-General Manager of Glaxo Pharmaceuticals. He is currently on the board of directors of BioDelivery Sciences International, Inc., where he serves as a member of the audit committee. He also serves on the boards of two private companies, Respirics, Inc., for whom he serves as chairman of the board, and Hematrope Pharmaceuticals. Mr. Butler is on the Pharmacy School Advisory Board at the University of Florida and is a member of the Board of Visitors at Campbell University, North Carolina.

POZEN is a pharmaceutical company developing therapeutic advances in a cost effective manner. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. Product development efforts are focused on diseases with unmet medical needs where POZEN can improve efficacy, safety, and/or patient convenience. The company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For detailed company information, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and FDA approval of our product candidates, resulting in, among other things, our failure to achieve milestones that would have provided us with revenue; our inability to enter into or maintain, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales, and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2003 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Matt Czajkowski
Chief Financial Officer
Lisa Barthelemy
Director, Investor Relations